Christopher Raymond
Stock Analyst at Raymond James
(2.73)
# 1,848
Out of 5,241 analysts
140
Total ratings
53.04%
Success rate
2.21%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Strong Buy | $46 | $22.87 | +101.14% | 1 | Mar 11, 2026 | |
| CLYM Climb Bio | Initiates: Strong Buy | $25 | $10.80 | +131.48% | 1 | Mar 11, 2026 | |
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $32.68 | +59.12% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $6.23 | +156.82% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $5.09 | +391.16% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $5.96 | +118.12% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $9.40 | +208.51% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $114.53 | -38.88% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $192.95 | -40.40% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $2.03 | +343.35% | 6 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $126 | $51.81 | +143.20% | 15 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $4 | $6.30 | -36.51% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $210.39 | +7.89% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $436.95 | +21.98% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $698.25 | +45.08% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $25.00 | +460.00% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $59.27 | +21.48% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $4.52 | +187.61% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $7.67 | +877.84% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $8.76 | +767.58% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $37.04 | -10.91% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.06 | +277.36% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $326.31 | -11.74% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $28.17 | +45.54% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $37.26 | -24.85% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $102.30 | -60.90% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $6.92 | +1,200.58% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.30 | +7,284.62% | 2 | Mar 13, 2020 |
Alumis
Mar 11, 2026
Initiates: Strong Buy
Price Target: $46
Current: $22.87
Upside: +101.14%
Climb Bio
Mar 11, 2026
Initiates: Strong Buy
Price Target: $25
Current: $10.80
Upside: +131.48%
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $32.68
Upside: +59.12%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $6.23
Upside: +156.82%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $5.09
Upside: +391.16%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $5.96
Upside: +118.12%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $9.40
Upside: +208.51%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $114.53
Upside: -38.88%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $192.95
Upside: -40.40%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $2.03
Upside: +343.35%
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $51.81
Upside: +143.20%
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $6.30
Upside: -36.51%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $210.39
Upside: +7.89%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $436.95
Upside: +21.98%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $698.25
Upside: +45.08%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $25.00
Upside: +460.00%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $59.27
Upside: +21.48%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $4.52
Upside: +187.61%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $7.67
Upside: +877.84%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $8.76
Upside: +767.58%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $37.04
Upside: -10.91%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.06
Upside: +277.36%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $326.31
Upside: -11.74%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $28.17
Upside: +45.54%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $37.26
Upside: -24.85%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $102.30
Upside: -60.90%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $6.92
Upside: +1,200.58%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.30
Upside: +7,284.62%